In this study, we employed MR to explore the causal relationships between cholesterol-lowering drug targets (HMGCR, PCSK9, and NPC1L1) and the risk of developing diabetic microvascular complications (including nephropathy, retinopathy, and neuropathy). Here, HMGCR is linked to Nephropathy.